The FDA panel Voted against the Obesity Drug Qnexa yesterday.

The advisory committee voted 10 to 6 against endorsing the weight loss drug Qnexa, signaling heightened concerns for possible health risks associated with a new generation of diet pills.

The F.D.A. is scheduled to decide by late October whether to approve Qnexa. It usually abides by the advice of its advisory committees.

The outcome of the advisory committee meeting on Qnexa could also mean a more difficult time for two other new weight loss drugs that will face advisory committee hearings this year. These are Lorcaserin from Arena Pharmaceuticals and Contrave from Orexigen Therapeutics.

We keep you posted here.